Breast cancer
Open accessThe DOI matches its Crossref record; 324 of the 324 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70–80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with distant organ metastases is considered incurable with currently available therapies. On the molecular level, breast cancer is a heterogeneous disease; molecular features include activation of human epidermal growth factor receptor 2 (HER2, encoded by ERBB2), activation of hormone receptors (oestrogen receptor and progesterone receptor) and/or BRCA mutations. Treatment strategies differ according to molecular subtype. Management of breast cancer is multidisciplinary; it includes locoregional (surgery and radiation therapy) and systemic therapy approaches. Systemic therapies include endocrine therapy for hormone receptor-positive disease, chemotherapy, anti-HER2 therapy for HER2-positive disease, bone stabilizing agents, poly(ADP-ribose) polymerase inhibitors for BRCA mutation carriers and, quite recently, immunotherapy. Future therapeutic concepts in breast cancer aim at individualization of therapy as well as at treatment de-escalation and escalation based on tumour biology and early therapy response. Next to further treatment innovations, equal worldwide access to therapeutic advances remains the global challenge in breast cancer care for the future.Breast cancer is the most frequent malignancy in women worldwide. Patients are managed on the basis of the key molecular and histological features underpinnin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased counts of tumour-infiltrating lymphocytes (TILs) are prognostic for survival in triple-negative breast cancer (TNBC), making this disease a potential target for immunotherapy.88”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [88]
Citations
Cites
Items 201–324 of 324
Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study
Ahmed, R. L., Schmitz, K. H., Prizment, A. E., & Folsom, A. R. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1667-z · Cited by 157
Immune Landscape of Breast Cancers
Nagarajan, D., & McArdle, S. (2018) · Biomedicines · doi:10.3390/biomedicines6010020 · Cited by 152
Joensuu, H., Fraser, J., Wildiers, H., Huovinen, R., Auvinen, P., Utriainen, M., Nyandoto, P., Villman, K. K., Halonen, P., Granstam-Björneklett, H., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1380 · Cited by 151
Nguyen, J., Popovic, M. M., Chow, E., Cella, D. F., Beaumont, J. L., Chu, D., DiGiovanni, J., Lam, H., Pulenzas, N., & Bottomley, A. (2015) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.14.76 · Cited by 150
Raina, V., Bhutani, M., Bedi, R., Sharma, A., Deo, S. V. S., Shukla, N., Mohanti, B., & Rath, G. (2005) · Indian Journal of Cancer · doi:10.4103/0019-509x.15099 · Cited by 150
Bandera, E. V., Maskarinec, G., Romieu, I., & John, E. M. (2015) · Advances in Nutrition · doi:10.3945/an.115.009647 · Cited by 150
Revicki, D. A., Kawata, A. K., Harnam, N., Chen, W.-H., Hays, R. D., & Cella, D. (2009) · Quality of Life Research · doi:10.1007/s11136-009-9489-8 · Cited by 147
Kunkler, I. H., Canney, P. A., van Tienhoven, G., & Russell, N. S. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.10.004 · Cited by 146
Nitz, U. A., Gluz, O., Clemens, M., Malter, W., Reimer, T., Nuding, B., Aktas, B., Stefek, A., Pollmanns, A., Lorenz-Salehi, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00028 · Cited by 144
Self-citationHanai, A., Ishiguro, H., Sozu, T., Tsuda, M., Yano, I., Nakagawa, T., Imai, S., Hamabe, Y., Toi, M., Arai, H., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx178 · Cited by 141
Forbes, C. A., Fayter, D., de Kock, S., & Quek, R. G. W. (2019) · Cancer Management and Research · doi:10.2147/cmar.s189627 · Cited by 141
Marinovich, M. L., Macaskill, P., Irwig, L., Sardanelli, F., Mamounas, E. P., von Minckwitz, G., Guarneri, V., Partridge, S. C., Wright, F. C., Choi, J. H., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1664-4 · Cited by 139
Self-citationBaselga, J., Dent, S. F., Cortés, J., Im, Y.-H., Diéras, V., Harbeck, N., Krop, I. E., Verma, S., Wilson, T. R., Jin, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba1006 · Cited by 138
Self-citationPennant, M., Takwoingi, Y., Pennant, L., Davenport, C., Fry-Smith, A., Eisinga, A., Andronis, L., Arvanitis, T., Deeks, J., & Hyde, C. (2010) · Health Technology Assessment · doi:10.3310/hta14500 · Cited by 135
Clinical implications of molecular heterogeneity in triple negative breast cancer
Lehmann, B. D., & Pietenpol, J. A. (2015) · The Breast · doi:10.1016/j.breast.2015.07.009 · Cited by 135
18F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer
Avril, S., Muzic, R. F., Plecha, D. M., Traughber, B. J., Vinayak, S., & Avril, N. E. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.157875 · Cited by 127
Mao, J. J., Bowman, M. A., Xie, S. X., Bruner, D., DeMichele, A., & Farrar, J. T. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9412 · Cited by 126
Hofmann, D., Nitz, U. A., Gluz, O., Kates, R. E., Schinköthe, T., Staib, P., & Harbeck, N. (2013) · Trials · doi:10.1186/1745-6215-14-261 · Cited by 124
Self-citationBuonomo, O. C., Caredda, E., Portarena, I., Vanni, G., Orlandi, A., Bagni, C., Petrella, G., Palombi, L., & Orsaria, P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184680 · Cited by 121
Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art
Solinas, C., Carbognin, L., Silva, P. D., Criscitiello, C., & Lambertini, M. (2017) · The Breast · doi:10.1016/j.breast.2017.07.005 · Cited by 119
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., Hudis, C. A., Hwang, E. S., Kirshner, J. J., Morrow, M., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5558-8 · Cited by 117
Schmid, P., Cruz, C., Braiteh, F. S., Eder, J. P., Tolaney, S., Kuter, I., Nanda, R., Chung, C., Cassier, P., Delord, J.-P., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2986 · Cited by 115
Ganz, P. A., Yip, C. H., Gralow, J. R., Distelhorst, S. R., Albain, K. S., Andersen, B. L., Bevilacqua, J. L. B., de Azambuja, E., El Saghir, N. S., Kaur, R., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.07.049 · Cited by 114
Boughey, J. C., Hieken, T. J., Jakub, J. W., Degnim, A. C., Grant, C. S., Farley, D. R., Thomsen, K. M., Osborn, J. B., Keeney, G. L., & Habermann, E. B. (2014) · Surgery · doi:10.1016/j.surg.2014.03.025 · Cited by 113
Coleman, R. E., Collinson, M., Gregory, W. M., Marshall, H. C., Bell, R., Dodwell, D. J., Keane, M., Gil, M., Barrett-Lee, P. J., Ritchie, D., et al. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.09.008 · Cited by 112
Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications
Reed, A. E. M., Kalaw, E., Nones, K., Bettington, M. L., Lim, M., Bennett, J., Johnstone, K. J., Kutasovic, J. R., Saunus, J. M., Kazakoff, S. H., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5184 · Cited by 105
Cobain, E. F., Milliron, K. J., & Merajver, S. D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.001 · Cited by 104
Vasudev, P., & Onuma, K. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2010-0351-rs · Cited by 103
Taylor, A., Brady, A. F., Frayling, I. M., Hanson, H., Tischkowitz, M., Turnbull, C., & Side, L. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-105188 · Cited by 101
Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W. J., Masuda, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1002 · Cited by 99
Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.003 · Cited by 98
Schulman, A., Mirrielees, J. A., LEVERSON, G. E., Landercasper, J., Greenberg, C. C., & Wilke, L. G. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5516-5 · Cited by 96
Amoroso, V., Generali, D., Buchholz, T. A., Cristofanilli, M., Pedersini, R., Curigliano, G., Daidone, M. G., Cosimo, S. D., Dowsett, M., Fox, S. B., et al. (2015) · JNCI Monographs · doi:10.1093/jncimonographs/lgv023 · Cited by 95
European Breast Cancer Conference manifesto on breast centres/units
Cardoso, F., Cataliotti, L., Costa, A., Knox, S., Marotti, L., Rutgers, E. J. T., & Beishon, M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.023 · Cited by 95
Self-citationBreast cancer in transgender patients: A systematic review. Part 1: Male to female
Hartley, R. L., Stone, J. P., & Temple‐Oberle, C. F. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.06.035 · Cited by 93
Surgical Management of the Breast
McLaughlin, S. A. (2013) · Surgical Clinics of North America · doi:10.1016/j.suc.2012.12.006 · Cited by 92
Velikova, G., Williams, L. J., Willis, S., Dixon, J. M., Loncaster, J. A., Hatton, M. Q. F., Clarke, J., Kunkler, I. H., Russell, N. S., Alhasso, A. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30515-1 · Cited by 91
Hilakivi‐Clarke, L., de Assis, S., & Wärri, A. M. (2013) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-013-9274-8 · Cited by 90
Phi, X.-A., Houssami, N., Obdeijn, I.-M., Warner, E., Sardanelli, F., Leach, M. O., Riedl, C. C., Trop, I., Tilanus‐Linthorst, M. M. A., Mandel, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.6232 · Cited by 90
Self-citationPostmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate
Poortmans, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60192-6 · Cited by 89
Self-citationRen, J.-X., Gong, Y., Ling, H., Hu, X., & Shao, Z. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4956-y · Cited by 84
Overdiagnosis of breast cancer in population screening: does it make breast screening worthless?
Nehmat, H., & Nehmat, H. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0050 · Cited by 82
Self-citationSoran, A., Özbaş, S., Kelsey, S. F., & Gulluoglu, B. M. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00744.x · Cited by 81
Crawford, B., Adams, S., Sittler, T., van den Akker, J., Chan, S. B., Leitner, O., Ryan, L. A., Gil, E., & Veer, L. V. ‘. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4181-0 · Cited by 81
Rugo, H. S., Im, S.-A., Wright, G. L. S., Escriva-de-Romani, S., DeLaurentiis, M., Cortes, J., Bahadur, S. W., Haley, B. B., Oyola, R. H., Riseberg, D. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1000 · Cited by 80
Self-citationYao, K. A., Winchester, D. J., Czechura, T., & Huo, D. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2745-1 · Cited by 80
Unmet Information Needs and Quality of Life in Young Breast Cancer Survivors in Japan
Miyashita, M., Ohno, S., Kataoka, A., Tokunaga, E., Masuda, N., Shien, T., Kawabata, K., & Takahashi, M. (2015) · Cancer Nursing · doi:10.1097/ncc.0000000000000201 · Cited by 75
Brouwers, P. J. A. M., van Werkhoven, E. D., Bartelink, H. G. M. M., Fourquet, A., Lemanski, C., van Loon, J., Maduro, J. H., Russell, N. S., Scheijmans, L. J. E. E., Schinagl, D. A. X., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.06.020 · Cited by 75
Self-citationBody mass index, mammographic density, and breast cancer risk by estrogen receptor subtype
Shieh, Y., Scott, C. G., Jensen, M. R., Norman, A. D., Bertrand, K. A., Pankratz, V. S., Brandt, K. R., Visscher, D. W., Shepherd, J., Tamimi, R. M., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1129-9 · Cited by 75
Effect of Endocrine Therapies on Bone in Breast Cancer Patients
Santen, R. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1679 · Cited by 74
Advancing breast cancer survivorship among African-American women
Coughlin, S. S., Yoo, W., Whitehead, M. S., & Smith, S. A. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3548-3 · Cited by 74
Siwko, S. K., Dong, J., Lewis, M. T., Liu, H., Hilsenbeck, S. G., & Li, Y. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0103 · Cited by 74
Coleman, R. E., Finkelstein, D. M., Barrios, C. H., Martín, M., Iwata, H., Glaspy, J. A., Zhou, Y. Y., Jandial, D., & Chan, A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.501 · Cited by 70
Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer
Humbert, O., Cochet, A., Coudert, B. P., Berriolo-Riedinger, A., Kanoun, S., Brunotte, F., & Fumoleau, P. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0342 · Cited by 68
André, F., Ciruelos, E. M., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.010 · Cited by 67
Supportive Cryotherapy: A Review From Head to Toe
Kadakia, K. C., Rozell, S. A., Butala, A. A., & Loprinzi, C. L. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.07.014 · Cited by 66
Poortmans, P. M., Aznar, M. C., & Bartelink, H. G. M. M. (2011) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2011.09.007 · Cited by 66
Self-citationPoortmans, P. M., Arenas, M., & Livi, L. (2016) · The Breast · doi:10.1016/j.breast.2016.07.022 · Cited by 66
Self-citationFietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., & Marschner, N. (2017) · The Breast · doi:10.1016/j.breast.2017.05.014 · Cited by 65
Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results
Golse, N., & Adam, R. A. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.12.012 · Cited by 65
Tolaney, S. M., Barry, W. T., Guo, H., Dillon, D. A. R., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.511 · Cited by 65
Mackey, J. R., Pieńkowski, T., Crown, J. P., Sadeghi, S., Martín, M., Chan, A., Saleh, M. N., Sehdev, S. R., Provencher, L., Семиглазов, В. Ф., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw098 · Cited by 63
Schmid, P., Abraham, J., Chan, S. Y. T., Wheatley, D. A., Brunt, M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1007 · Cited by 61
Evidence relevant to the investigation of breast symptoms: the triple test
Irwig, L., Macaskill, P., & Houssami, N. (2002) · The Breast · doi:10.1054/brst.2001.0409 · Cited by 60
Self-citationSurgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy
Buchholz, T. A., Mittendorf, E., & Hunt, K. K. (2015) · JNCI Monographs · doi:10.1093/jncimonographs/lgv020 · Cited by 58
Jatoi, I., Benson, J. R., & Kunkler, I. H. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0061-y · Cited by 58
Dodwell, D. J., Taylor, C., McGale, P., Coles, C. E., Duane, F. K., Gray, R. G., Kühn, T., Hennequin, C., Oliveros, S., Wang, X., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-gs4-02 · Cited by 58
Self-citationCurigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P. C., Loibl, S., Colleoni, M., Regan, M. M., Piccart, M. J., Senn, H.-J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx806 · Cited by 56
Self-citationBreast cancer risk of hormonal contraception: Counselling considering new evidence
Pup, L. D., Codacci-Pisanelli, G., & Peccatori, F. A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.03.001 · Cited by 55
Suhrke, P., Mæhlen, J., Schlichting, E., Jørgensen, K. J., Gøtzsche, P. C., & Zahl, P. (2011) · BMJ · doi:10.1136/bmj.d4692 · Cited by 54
Stevens–Johnson syndrome during nivolumab treatment of NSCLC
Salati, M., Pifferi, M., Baldessari, C., Bertolini, F., Tomasello, C., Cascinu, S., & Barbieri, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx640 · Cited by 54
Hölzel, D., Eckel, R., Bauerfeind, I., Baier, B., Beck, T., Braun, M., Ettl, J., Hamann, U., Kiechle, M. B., Mahner, S., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2428-0 · Cited by 53
Self-citationZhang, K., Hong, R., Xu, F., Xia, W., Lee, K., Qin, G., Zheng, Q., Lu, Q., Shi, Y. X., Yuan, Z. Y., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s173193 · Cited by 52
Busund, M., Bugge, N. S., Braaten, T., Waaseth, M., Rylander, C., & Lund, E. (2018) · International Journal of Cancer · doi:10.1002/ijc.31266 · Cited by 51
Thavarajah, N., Wong, K., Zhang, L., Bedard, G. D., Wong, E., Tsao, M. N., Danjoux, C. E., Barnes, E. A., Sahgal, A., Dennis, K. E. B., et al. (2013) · Current Oncology · doi:10.3747/co.20.1342 · Cited by 48
Chung, A. P., Gangi, A., Amersi, F. F., Bose, S., Zhang, X., & Giuliano, A. E. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4829-0 · Cited by 48
The impact of legislation mandating breast density notification – Review of the evidence
Houssami, N., & Lee, C. I. (2018) · The Breast · doi:10.1016/j.breast.2018.09.001 · Cited by 47
Self-citationGreen, A. R., Soria, D., Stephen, J., Powe, D. G., Nolan, C. C., Kunkler, I. H., Thomas, J. S. J., Kerr, G. R., Jack, W. J. L., Cameron, D., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.32 · Cited by 46
Wong, F. Y., Tham, W. Y., Nei, W. L., Lim, C., & Miao, H. (2018) · 癌症:英文版 · doi:10.1186/s40880-018-0310-3 · Cited by 46
Burris, J. L., Armeson, K., & Sterba, K. R. (2015) · Behavioral Medicine · doi:10.1080/08964289.2014.889068 · Cited by 45
Gingras, I., Salgado, R., & Ignatiadis, M. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000223 · Cited by 44
Boudreau, A., van't Veer, L. J., & Bissell, M. J. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20880 · Cited by 43
Krug, D. A., Baumann, R., Budach, W., Dunst, J., Feyer, P., Fietkau, R., Haase, W., Harms, W., Hehr, T., Piroth, M. D., et al. (2018) · Strahlentherapie und Onkologie · doi:10.1007/s00066-018-1270-x · Cited by 43
Jones, R. H., Carucci, M., Casbard, A. C., Butler, R., Alchami, F., Bale, C. J., Bezecny, P., Joffe, J., Moon, S., Twelves, C. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1005 · Cited by 43
Local treatment of metastatic cancer—killing the seed or disturbing the soil?
Morgan, S. C., & Parker, C. C. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.88 · Cited by 42
BMI change and abdominal circumference are risk factors for breast cancer, even in Asian women
Suzuki, Y., Tsunoda, H. S., Kimura, T., & Yamauchi, H. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4481-4 · Cited by 42
Survival of de novo stage IV breast cancer patients over three decades
Hölzel, D., Eckel, R., Bauerfeind, I., Baier, B., Beck, T., Braun, M., Ettl, J., Hamann, U., Harbeck, N., Kiechle, M. B., et al. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2306-1 · Cited by 38
Self-citationTranslational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer
Yates, L. R., & Desmedt, C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2548 · Cited by 38
Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis
Liang, M., Zhang, Y., Sun, C., Rizeq, F. K., Min, M., Shi, T., & Sun, Y. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0344-x · Cited by 37
McLachlan, S., Devins, G. M., & Goodwin, P. J. (1999) · Quality of Life Research · doi:10.1023/a:1008939818096 · Cited by 35
Τζιώτου, Μ., Kalotychou, V., Ntokou, A., Tzanetea, R., Armenis, I., Varsou, M., Κωνσταντόπουλος, Κ., Tsavaris, N. B., & Rombos, Y. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.428 · Cited by 35
Should breathing adapted radiotherapy also be applied for right-sided breast irradiation?
Essers, M., Poortmans, P. M., Verschueren, K. M. S., Hol, S., & Cobben, D. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1102321 · Cited by 34
Self-citationPIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer
Deb, S., Do, H., Byrne, D. J., Jene, N., kConFab Investigators, Dobrovic, A., & Fox, S. B. (2013) · Breast Cancer Research · doi:10.1186/bcr3463 · Cited by 34
Immuno-oncology: Allying forces of radio- and immuno-therapy to enhance cancer cell killing
Bernier, J. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.001 · Cited by 34
Gray, R. G., Bradley, R., Braybrooke, J. P., Davies, C., Pan, H., Peto, R., Bliss, J. M., Cameron, D., Mackey, J. R., Mastro, L. D., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-gs1-01 · Cited by 34
Robertson, J., Dowsett, M., Bliss, J. M., Morden, J. P., Wilcox, M., Evans, A. A., Holcombe, C., Horgan, K. J., Kirwan, C., Mallon, E., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-gs1-03 · Cited by 33
A review of estrogen receptor/androgen receptor genomics in male breast cancer
Severson, T., & Zwart, W. T. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0225 · Cited by 32
Stang, A., Kääb-Sanyal, V., Hense, H., Becker, N., & Kuß, O. (2013) · European Journal of Epidemiology · doi:10.1007/s10654-013-9816-9 · Cited by 31
Tan, M. P.-C., Sitoh, N. Y., & Sim, A. S. (2014) · International Journal of Breast Cancer · doi:10.1155/2014/715404 · Cited by 30
Inflammatory breast cancer: The pathologists' perspective
Cserni, G., Charafe‐Jauffret, E., & van Diest, P. J. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.04.001 · Cited by 29
Recent Advances in Breast Cancer Genetics
Pasche, B. (2007) · Cancer treatment and research · doi:10.1007/978-0-387-73161-2_1 · Cited by 28
Management of breast cancer brain metastases: A practical review
Phillips, C., Jeffree, R. L., & Khasraw, M. (2016) · The Breast · doi:10.1016/j.breast.2016.10.006 · Cited by 28
Wang, X., Teer, J. K., Tousignant, R. N., Levin, A. M., Boulware, D. C., Chitale, D. A., Shaw, B. M., Chen, Z., Zhang, Y., Blakeley, J. O., et al. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22503 · Cited by 28
Barinoff, J., Schmidt, M., Schneeweiß, A., Schoenegg, W., Thill, M., Keitel, S., Lattrich, C., Hinke, A., Kutscheidt, A., & Jackisch, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.002 · Cited by 27
Margenthaler, J. A., & Ollila, D. W. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5369-y · Cited by 26
Lee, C. I., Gold, L. S., Nelson, H. D., Chou, R., Ramsey, S. D., & Sullivan, S. D. (2014) · The Breast · doi:10.1016/j.breast.2014.11.009 · Cited by 25
Hyman, D. M., Piha-Paul, S. A., Rodon, J. A., Saura, C., Shapiro, G. I., Quinn, D. I., Moreno, V., Mayer, I. A., Arteaga, C. L., Boni, V., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct001 · Cited by 23
Breast Cancer Mortality in Older and Younger Patients in California
Li, T., Schwab, R. B., Miguel, Y. S., Gomez, S., Canchola, A., Gago-Domínguez, M., Komenaka, I., Murphy, J., Molinolo, A., & Martínez, M. E. (2018) · Cancer Epidemiology, Biomarkers and Prevention · doi:10.1158/1055-9965.epi-18-0353 · Cited by 21
Xie, Y., Lv, X., Luo, C., Hu, K., Gou, Q., Xie, K., & Zheng, H. Y. (2017) · Medicine · doi:10.1097/md.0000000000007048 · Cited by 19
Barton, D. L., Sloan, J. A., Shuster, L. T., Gill, P., Bearden, J. D., Johnson, D. B., Stella, P. J., Terstriep, S. A., Rana, F. N., Anderson, D. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9507 · Cited by 17
Appropriate margin for lumpectomy excision of invasive breast cancer
Barrio, A. V., & Morrow, M. (2016) · Chinese Clinical Oncology · doi:10.21037/cco.2016.03.22 · Cited by 17
Accelerated partial breast irradiation: Current status with a focus on clinical practice
Miranda, F. A., Teixeira, L. A. B., Heinzen, R. N., Andrade, F., Hijal, T., Buchholz, T. A., de Moraes, F. Y., Poortmans, P. M., & Marta, G. N. (2018) · The Breast Journal · doi:10.1111/tbj.13164 · Cited by 16
Self-citationMarta, G. N., Barrett, J., Porfírio, G. J. M., Martimbianco, A. L. C., Bevilacqua, J. L. B., Poortmans, P. M., & Riera, R. (2019) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2019.01.009 · Cited by 15
Self-citationShien, T., Mizutani, T., Tanaka, K., Kinoshita, T., Hara, F., Fujisawa, T., Masuda, N., Tamura, K., Hojo, T., Kanbayashi, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps588 · Cited by 14
X chromosome gain is related to increased androgen receptor expression in male breast cancer
Oto, E. D., Biserni, G. B., Varga, Z., Morandi, L., Cucchi, M. C., Masetti, R., & Foschini, M. P. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2377-2 · Cited by 13
Resection of the primary tumor in stage IV breast cancer
Shien, T. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i2.82 · Cited by 11
Removing the primary tumour in metastatic breast cancer
Cameron, D. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00221-1 · Cited by 9
The debate over post-mastectomy radiotherapy should continue
Oliai, C. H., & Hurvitz, S. A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.147 · Cited by 7
Bjelic‐Radisic, V., Bottomley, A., Cardoso, F., Cameron, D., Brain, E. G. C., Kuljanić, K., Costa, R. A., Conroy, T., Inwald, E., Serpentini, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy270.267 · Cited by 7
Self-citationReverse effect of chidamide on endocrine resistance in estrogen receptor-positive breast cancer
ZHOU, Y., WANG, Y., ZHANG, K., ZHU, J., & NING, Z. (2018) · Journal of Shenzhen University Science and Engineering · doi:10.3724/sp.j.1249.2018.04339 · Cited by 6
Burris, H. A., Giaccone, G., Im, S., Bauer, T. M., Oh, D., Jones, S. F., Nordstrom, J. L., Li, H., Carlin, D. A., Baughman, J. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.523 · Cited by 5
Abstract GS1-07: The genomic landscape of 501 metastatic breast cancer patients
Angus, L., Wilting, S. M., van Riet, J., Smid, M., Steenbruggen, T. G., Tjan‐Heijnen, V. C. G., Labots, M., van Riel, J., Bloemendal, H., Steeghs, N., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-gs1-07 · Cited by 3
Approach towards re-irradiation of common cancers
Bandyopadhyay, A., Patro, K., Basu, P., & Roy, K. (2018) · Journal of Current Oncology · doi:10.4103/jco.jco_7_17 · Cited by 2
“Between Uncertainties and Overtreatment”
Kaidar‐Person, O., Meattini, I., & Poortmans, P. M. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.02.027 · Cited by 1
Self-citation
Research works printed but not linked: 11
- Hossain, M. S., Ferdous, S. & Karim-Kos, H. E. Breast cancer in South. Asia: a Bangladeshi perspective. Cancer Epidemiol. 38, 465–470 (2014).
- Li, C. I., Malone, K. E. & Daling, J. R. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol. Biomark. Prev. 11, 601–607 (2002).
- World Heath Organisation. WHO Classification of Tumours of the Breast, Fourth Edition. (World Health Organization, 2012).
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771–784 (2011). · DOI · Paper page
- Dare, A. J. et al. Surgical Services for Cancer Care. in Cancer: Disease Control Priorities, Third Edition (Volume 3) (eds. Gelband, H., Jha, P., Sankaranarayanan, R. & Horton, S.) (The International Bank for Reconstruction and Development/The World Bank, 2015).
- Sologuren, I., Rodríguez-Gallego, C. & Lara, P. C. Immune effects of high dose radiation treatment: implications of ionizing radiation on the development of bystander and abscopal effects. Transl Cancer Res. 3, 18-31–31 (2014).
- Morgan, S., Caudrelier, J.-M. & Clemons, M. Radiotherapy to the primary tumor is associated with improved survival in stage IV breast cancer [abstract]. SABCS P4, 16–06 (2012).
- Hou, S., Huh, B., Kim, H. K., Kim, K.-H. & Abdi, S. Treatment of chemotherapy-induced peripheral neuropathy: systematic review and recommendations. Pain Physician 21, 571–592 (2018).
- Desmedt, C. et al. Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples [abstract]. SABCS GS1–06 (2018).
- Cortes, J., Crown, J. & Awada, A. Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC) [abstract]. Eur. Cancer Congr. 51 (Suppl. 3), 1802 (2015).
- Hoadley, K. A., Andre, F., Ellis, M. J. & Perou, C. M. Breast cancer intrinsic subtypes (Poster). Nat. Rev. Clin. Oncol. https://www.nature.com/documents/nrclinonc_posters_breastcancer.pdf (2014).
Cited by
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Self-citationPyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“Few (88) of these patients were treated in the CLEOPATRA trial and all with a trastuzumabfree interval >12 months.”
BackgroundSelf-citationTrastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083
Self-citation
Metadata
- Authors
- Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F.
- Affiliations
- LMU Klinikum (DE)
- Medical University of Vienna (AT)
- The University of Sydney (AU)
- Université Paris Sciences et Lettres (FR)
- Mayo Clinic (US)
- University of Hong Kong (HK)
- Corresponding author
- Harbeck, Nadia
- Venue
- Nature Reviews Disease Primers
- Published
- 2019-09-23
- Volume
- 5
- Issue
- 1
- Pages
- 66-66
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4211005384
- Cited by
- 3,024
- References
- 324
- Citations by year
- 2026: 344 · 2025: 500 · 2024: 536 · 2023: 510 · 2022: 503 · 2021: 425 · 2020: 195 · 2019: 8
- FWCI
- 27.21
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Disease Primers (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- The Sydney eScholarship Repository (The University of Sydney) (submittedVersion)
- The Sydney eScholarship Repository (The University of Sydney) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (KL2TR002379)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- breast cancer, HER2, oestrogen receptor, progesterone receptor, BRCA mutations, molecular subtypes, endocrine therapy, chemotherapy, HER2-targeted therapy, PARP inhibitors, immunotherapy, locoregional therapy, systemic therapy, treatment de-escalation, treatment escalation, personalized treatment, access to cancer care
- MeSH terms
- Adult, Breast Neoplasms, Female, Humans, Biomarkers, Tumor, Survivors, Erb-b2 Receptor Tyrosine Kinases, BRCA2 Protein, Ubiquitin-Protein Ligases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.